Oppenheimer Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $15.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective cut by Oppenheimer from $20.00 to $15.00 in a report released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

YMAB has been the subject of a number of other research reports. HC Wainwright reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Truist Financial reduced their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Wedbush reiterated an “outperform” rating and issued a $18.00 price target (down previously from $21.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Tuesday, April 22nd. Finally, Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.60.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $4.71 on Thursday. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The stock has a market cap of $213.29 million, a PE ratio of -8.72 and a beta of 0.53. The firm has a fifty day moving average price of $4.37 and a 200 day moving average price of $6.33.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $20.90 million during the quarter, compared to analysts’ expectations of $19.97 million. As a group, equities analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 10,810 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 22.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of YMAB. Brooklyn Investment Group raised its position in Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock worth $26,000 after acquiring an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $49,000. Corton Capital Inc. purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $55,000. Finally, EntryPoint Capital LLC purchased a new position in Y-mAbs Therapeutics in the first quarter valued at about $56,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.